Speaker Profile
PhD, Chief of Public Mental Health & Population Sciences, Stanford
Biography
Dr. Kaysen is a clinical psychologist and health services researcher. Her area of specialty in research and clinical work is in treatment of PTSD and related disorders. She has conducted critical studies on treatment of PTSD and comorbid conditions across types of trauma events especially those disproportionately affecting women such as sexual assault and child sexual abuse. Her work expands treatment to diverse populations (e.g. Native Americans, sexual and gender minorities, Latinos) and across settings (e.g. primary care, community, low and middle income countries) and means of treatment delivery (telehealth, digital health, text based). Dr. Kaysen is a past President of the International Society for Traumatic Stress Studies (www.istss.org). Dr. Kaysen's has over 180 research publications and her research has been funded by NIH, the Department of Defense, and The PatientCentered Outcomes Research Institute (PCORI). Her clinical work has been featured on This American Life.
Talk
Gender Effects on Trauma Exposure, PTSD, and Treatment
Gender influences risk of overall trauma exposure, risk of specific types of traumatic events, and risk of development of PTSD. Women and gender minorities have higher risk of interpersonal violence and of PTSD. In contrast, women generally have a more robust treatment response. This has implications for personalized prevention and treatment.
Clinical Dx Showcase:
Stanford University
The Department of Psychiatry and Behavioral Sciences of Stanford Medicine has an overarching aim to enable great science, prepare exceptional people, and inspire an engaged society to create a better future for all whose lives are affected by mental illness.
Session Abstract – PMWC 2024 Silicon Valley
The PMWC 2024 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
